WO1989001489A1 - Regulation de l'angiogenese et compositions et procedes prevus a cet effet - Google Patents
Regulation de l'angiogenese et compositions et procedes prevus a cet effet Download PDFInfo
- Publication number
- WO1989001489A1 WO1989001489A1 PCT/AU1988/000300 AU8800300W WO8901489A1 WO 1989001489 A1 WO1989001489 A1 WO 1989001489A1 AU 8800300 W AU8800300 W AU 8800300W WO 8901489 A1 WO8901489 A1 WO 8901489A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tyr
- gly
- acm
- peptide
- angiogenesis
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 19
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 13
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract description 9
- 230000026341 positive regulation of angiogenesis Effects 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 230000002491 angiogenic effect Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 150000001413 amino acids Chemical group 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229920003345 Elvax® Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010012646 Diabetic blindness Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- -1 aceto amido methyl Chemical group 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Angiogenesis is the development of blood vessels.
- agents which will permit control of angiogenesis is of considerable interest in medical science and to associated industries; substances which stimulate angiogenesis may, for instance, have value in promoting wound healing, while inhibitors of angiogenesis could find application for retarding tumor growth or blocking the onset of diabetic blindness.
- Angiogenic properties are exhibited by a variety of agents.
- agents such as extracts of carcinoma cells or of normal bovine parotid glands; partially purified fractions of substances from Walker carcinoma cells, bovine parotid cells or bovine liver have been shown to be angiogenic by occular implant and chick chorioallantoic membrane assays. It has also been shown that low concentrations of ' copper ions can induce neovascularisation in the anterior eye chamber or corneal pocket.
- EGF epidermal growth factor
- a method for stimulating angiogenesis in animals characterised by the step of administering to an animal an effective amount of an angiogenically stimulating synthetic peptide having an amino acid sequence substantially corresponding to an amino acid sequence occurring in EGF, excluding EGF.
- amino acid is to be understood to embrace amino acid substitutes as recognized in the art.
- the present invention provides a synthetic peptide, which is active in stimulating angiogenesis in animals, having an amino acid sequence substantially corresponding to an amino acid sequence occurring in epidermal growth factor (EGF), excluding EGF.
- EGF epidermal growth factor
- the present invention provides a composition for use in the stimulation of angiogenesis comprising an effective amount of a synthetic peptide, which is active in stimulating angiongenesis, having an amino acid sequence substantially corresponding to an amino acid sequence occurring in epidermal growth factor (EGF), excluding EGF, and a pharmaceutically acceptable carrier.
- the active sequences may be identified using a cell migration assay as a screen system, together with an in vivo assay that minimises inflammation.
- the present inventor has using these techniques, identified synthetic peptide known amino acid sequences that induce angiogenesis by a medium involving (or consistent with) direct action on endothelial cells.
- the amino acid sequence for naturally occurring EGF is shown in Figure 1. Those sequences identified as active are: 3 - 14 3 - 10 12 - 14 12 - 15 29 - 37 33 - 37 Analogues or derivatives of these sequences, including small sub-fragments are also included in the scope of the invention.
- a line of capillary endothelial cells free from neural cells was prepared from bovine retinas McAuslan et al 1986 (In Vitro Models for Cancer Research. Chemical Rubber Co.
- Epidermal Growth Factor was used in the form described by McAuslan 1985 (Cell Biol. Int. Reports 9 ⁇
- EGF fragments were synthesised using a combined chemical-enzyme procedure described by Widmer et al in
- Oet oxyethyl ester
- ACM aceto amido methyl.
- BOC tertiary butyl oxycarbonyl.
- NH 2 amide on a carboxyl terminal group.
- BZ benzoyl. and conventional abbreviations are used for amino acid moieties.
- the angiogenic compounds according to this invention may find application in a variety of clinical fields. They may be used, for instance to enhance the healing of burns and wounds (especially those involving tissue defects); ( ⁇ ) to promote the acceptance of skin or organ grafts; (iii) in reconstructive and cosmetic surgery (including subdermal implants); and (iv) in prosthetic surgery, particularly where involved in vascular prosthesis.
- the compounds may be administered singly, in association with each or in association with angiogenic stimulator in different molecular species. Additionally, they are suitable for release from biodegradable matrices and by slow-release techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Des peptides synthétiques, qui ont une action de stimulation de l'angiogenèse chez les animaux, comportent des séquences correspondant sensiblement aux séquences d'acides aminés présentes dans le facteur de la croissance épidermique. Des compositions contenant ces peptides synthétiques et un procédé de stimulation de l'angiogenèse chez les animaux sont également décrits.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPI3629 | 1987-08-10 | ||
| AU362987 | 1987-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1989001489A1 true WO1989001489A1 (fr) | 1989-02-23 |
Family
ID=3694090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU1988/000300 WO1989001489A1 (fr) | 1987-08-10 | 1988-08-10 | Regulation de l'angiogenese et compositions et procedes prevus a cet effet |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1989001489A1 (fr) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992003476A1 (fr) * | 1990-08-13 | 1992-03-05 | Board Of Regents, The University Of Texas System | Peptides de facteur de croissance epidermique biologiquement actifs favorisant la regeneration tissulaire et le traitement du cancer |
| WO2000037095A1 (fr) * | 1998-12-21 | 2000-06-29 | The Victor Chang Cardiac Research Institute | Fonction et manipulation du muscle cardiaque |
| US7662772B2 (en) | 1999-04-23 | 2010-02-16 | Acorda Therapeutics, Inc. | Methods for treating congestive heart failure |
| US7795212B2 (en) | 2002-05-24 | 2010-09-14 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods and compositions for treating cardiovascular diseases |
| US8476405B2 (en) | 2005-12-02 | 2013-07-02 | Zensun (Shanghai) Science & Technology Ltd. | Neuregulin variants and methods of screening and using thereof |
| US10561709B2 (en) | 2014-10-17 | 2020-02-18 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure |
| US10702585B2 (en) | 2014-01-03 | 2020-07-07 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Formula of neuregulin preparation |
| US11179323B2 (en) | 2013-05-22 | 2021-11-23 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for treating heart failure |
| US11253573B2 (en) | 2011-10-10 | 2022-02-22 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure |
| US11638746B2 (en) | 2005-12-30 | 2023-05-02 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for improved cardiac function |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3917824A (en) * | 1973-03-28 | 1975-11-04 | Ici Ltd | Pharmaceutical compositions containing epidermal growth factor or closely related derivatives thereof for inhibiting the secretion of acidic gastric juice in warm blooded animals |
| US3948875A (en) * | 1973-11-27 | 1976-04-06 | Stanley Cohen | Process for the preparation of epidermal growth factor and new derivative using cross-linked polyacrylamide gel at a pH of 1-3 |
| JPS5927858A (ja) * | 1982-08-05 | 1984-02-14 | Nippon Shinyaku Co Ltd | ポリペプチドの製法 |
| US4490365A (en) * | 1980-08-04 | 1984-12-25 | Commonwealth Scientifique & Industrial Research Organization | Defleecing compounds |
| WO1985000369A1 (fr) * | 1983-07-05 | 1985-01-31 | Chiron Corporation | Synthese a l'aide d'adn hybride du facteur de croissance epidermique |
| AU3439084A (en) * | 1983-09-14 | 1985-04-11 | Komoriya, A. | Synthetic peptides with egf like activity and pharmaceutical compositions and methods of use |
| EP0205051A1 (fr) * | 1985-05-30 | 1986-12-17 | ZAMBON S.p.A. | Composition pharmaceutique sous forme d'une pommade pour application dermique et ophtalmique |
| JPS6217402A (ja) * | 1985-07-12 | 1987-01-26 | ヴイツカ−ズ，インコ−ポレ−テツド | 油圧制御装置 |
| JPS62149622A (ja) * | 1985-12-24 | 1987-07-03 | Wakunaga Pharmaceut Co Ltd | 腸機能改善剤 |
| US4686283A (en) * | 1985-04-16 | 1987-08-11 | Syntex (U.S.A.) Inc. | Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis |
| JPS633791A (ja) * | 1986-06-25 | 1988-01-08 | Hitachi Ltd | プラスミド組換え体 |
| JPS6377823A (ja) * | 1986-09-19 | 1988-04-08 | Fujisawa Pharmaceut Co Ltd | 抗癌剤 |
| US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
| EP0224885B1 (fr) * | 1985-11-28 | 1992-05-20 | Wakunaga Seiyaku Kabushiki Kaisha | Composition antitumorale. |
-
1988
- 1988-08-10 WO PCT/AU1988/000300 patent/WO1989001489A1/fr unknown
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3917824A (en) * | 1973-03-28 | 1975-11-04 | Ici Ltd | Pharmaceutical compositions containing epidermal growth factor or closely related derivatives thereof for inhibiting the secretion of acidic gastric juice in warm blooded animals |
| US3948875A (en) * | 1973-11-27 | 1976-04-06 | Stanley Cohen | Process for the preparation of epidermal growth factor and new derivative using cross-linked polyacrylamide gel at a pH of 1-3 |
| US4490365A (en) * | 1980-08-04 | 1984-12-25 | Commonwealth Scientifique & Industrial Research Organization | Defleecing compounds |
| JPS5927858A (ja) * | 1982-08-05 | 1984-02-14 | Nippon Shinyaku Co Ltd | ポリペプチドの製法 |
| WO1985000369A1 (fr) * | 1983-07-05 | 1985-01-31 | Chiron Corporation | Synthese a l'aide d'adn hybride du facteur de croissance epidermique |
| AU3439084A (en) * | 1983-09-14 | 1985-04-11 | Komoriya, A. | Synthetic peptides with egf like activity and pharmaceutical compositions and methods of use |
| US4686283A (en) * | 1985-04-16 | 1987-08-11 | Syntex (U.S.A.) Inc. | Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis |
| EP0205051A1 (fr) * | 1985-05-30 | 1986-12-17 | ZAMBON S.p.A. | Composition pharmaceutique sous forme d'une pommade pour application dermique et ophtalmique |
| JPS6217402A (ja) * | 1985-07-12 | 1987-01-26 | ヴイツカ−ズ，インコ−ポレ−テツド | 油圧制御装置 |
| EP0224885B1 (fr) * | 1985-11-28 | 1992-05-20 | Wakunaga Seiyaku Kabushiki Kaisha | Composition antitumorale. |
| JPS62149622A (ja) * | 1985-12-24 | 1987-07-03 | Wakunaga Pharmaceut Co Ltd | 腸機能改善剤 |
| US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
| JPS633791A (ja) * | 1986-06-25 | 1988-01-08 | Hitachi Ltd | プラスミド組換え体 |
| JPS6377823A (ja) * | 1986-09-19 | 1988-04-08 | Fujisawa Pharmaceut Co Ltd | 抗癌剤 |
Non-Patent Citations (5)
| Title |
|---|
| DERWENT WPI/L ONLINE ABSTRACT ACCESSION NO. 88-046257/07; & JP,A,63 003 791 (HITACHI K.K. AND HITACHI CHEMICAL K.K.), 8 January 1988 (08.01.88). * |
| DERWENT WPI/L ONLINE ABSTRACT ACCESSION NO. 88-136324/20; & JP,A,63 077 823 (FUJISAWA PHARM K.K.), 8 April 1988 (08.04.88). * |
| PATENT ABSTRACTS OF JAPAN, C-225, page 70; & JP,A,59 027 858 (NIPPON SHINYAKU K.K.; YAJIMA, H.), 14 February 1984 (14.02.84). * |
| PATENT ABSTRACTS OF JAPAN, C-463, page 118; & JP,A,62 149 622 (WAKUNAGA PHARMACEUT CO LTD; UDA, N.), 3 July 1987 (03.07.87). * |
| PATENT ABSTRACTS OF JAPAN, C-470, page 12; & JP,A,62 017 402 (WAKUNAGA PHARMACEUT CO LTD; KAKIMOTO, M.), 30 July 1987 (30.07.87). * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992003476A1 (fr) * | 1990-08-13 | 1992-03-05 | Board Of Regents, The University Of Texas System | Peptides de facteur de croissance epidermique biologiquement actifs favorisant la regeneration tissulaire et le traitement du cancer |
| WO2000037095A1 (fr) * | 1998-12-21 | 2000-06-29 | The Victor Chang Cardiac Research Institute | Fonction et manipulation du muscle cardiaque |
| US7226907B1 (en) | 1998-12-21 | 2007-06-05 | Zensun (Shanghai) Science & Technology Limited | Cardiac muscle function and manipulation |
| US7612164B2 (en) | 1998-12-21 | 2009-11-03 | Zensun (Shanghai) Science and Technologies Ltd. | Cardiac muscle function and manipulation |
| US7964555B2 (en) | 1998-12-21 | 2011-06-21 | Zensun (Shanghai) Sci & Tech Co., Ltd. | Cardiac muscle function and manipulation |
| US7662772B2 (en) | 1999-04-23 | 2010-02-16 | Acorda Therapeutics, Inc. | Methods for treating congestive heart failure |
| US10232016B2 (en) | 1999-04-23 | 2019-03-19 | Acorda Therapeutics, Inc. | Methods for treating congestive heart failure |
| US8076283B2 (en) | 1999-04-23 | 2011-12-13 | Acorda Therapeutics, Inc. | Methods for treating congestive heart failure |
| US8394761B2 (en) | 1999-04-23 | 2013-03-12 | Beth Israel Deaconess Medical Center | Methods for treating congestive heart failure |
| US8785387B2 (en) | 2002-05-24 | 2014-07-22 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods and compositions for treating cardiovascular disease |
| US9555076B2 (en) | 2002-05-24 | 2017-01-31 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin based methods and compositions for treating cardiovascular diseases |
| US7795212B2 (en) | 2002-05-24 | 2010-09-14 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods and compositions for treating cardiovascular diseases |
| US8476405B2 (en) | 2005-12-02 | 2013-07-02 | Zensun (Shanghai) Science & Technology Ltd. | Neuregulin variants and methods of screening and using thereof |
| US9340597B2 (en) | 2005-12-02 | 2016-05-17 | Zensun (Shanghai) Science And Technology Ltd. | Neuregulin variants and methods of screening and using thereof |
| US10112983B2 (en) | 2005-12-02 | 2018-10-30 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin variants and methods of screening and using thereof |
| US11638746B2 (en) | 2005-12-30 | 2023-05-02 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for improved cardiac function |
| US11253573B2 (en) | 2011-10-10 | 2022-02-22 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure |
| US11179323B2 (en) | 2013-05-22 | 2021-11-23 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for treating heart failure |
| US10702585B2 (en) | 2014-01-03 | 2020-07-07 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Formula of neuregulin preparation |
| US11969458B2 (en) | 2014-01-03 | 2024-04-30 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Formula of neuregulin preparation |
| US10561709B2 (en) | 2014-10-17 | 2020-02-18 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI257307B (en) | Pharmaceutical composition for cardiac tissue repair | |
| Childs et al. | Serum contains a platelet-derived transforming growth factor. | |
| Carpenter et al. | Epidermal growth factor | |
| CA2387247C (fr) | Utilisation d'agents neutralisants a facteurs de croissance pour la reduction de la cicatrisation | |
| Klagsbrun et al. | Regulators of angiogenesis | |
| CA2835369C (fr) | Fragments peptidiques destines a induire la synthese de proteines matricielles extracellulaires | |
| US5958874A (en) | Recombinant fibronectin-based extracellular matrix for wound healing | |
| Reddi | Collagen and cell differentiation | |
| JPS59501905A (ja) | 動物組織の修復 | |
| US20090111738A1 (en) | Fibronectin polypeptides and methods of use | |
| CA2078547A1 (fr) | Methode permettant d'accelerer la reparation des tissus chez les mammiferes | |
| CN1083392A (zh) | 用作蛋白质药物释放的含胶原海绵 | |
| DE602004005564T2 (de) | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten | |
| JP2510503B2 (ja) | 脳由来細胞増殖因子 | |
| WO1989001489A1 (fr) | Regulation de l'angiogenese et compositions et procedes prevus a cet effet | |
| EP0675728B1 (fr) | Produits et procedes destines a ameliorer l'adhesion du keratinocyte sur le derme | |
| Phillips et al. | An angiogenic extract from skeletal muscle stimulates monocyte and endothelial cell chemotaxis in vitro | |
| CA2321933C (fr) | Matrice extracellulaire a base de peptides de fibronectine utilisee dans la cicatrisation des blessures | |
| Welsch et al. | Adrenomedullin in mammalian and human skin glands including the mammary gland | |
| JPH0418865B2 (fr) | ||
| US7820172B1 (en) | Laminin-derived multi-domain peptides | |
| US5770562A (en) | Products and methods for improving keratinocyte adhesion to the dermis | |
| JP2000511155A (ja) | ヒトＭＰ５２ Ａｒｇタンパク質 | |
| KR20180076043A (ko) | 세포 투과능 및 골조직 재생능을 가지고 있는 이중 기능성 신규 펩타이드 및 이의 용도 | |
| Bhide et al. | Promotion of wound collagen formation in normal and diabetic mice by quadrol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |